Mn Services Vermogensbeheer B.V. Purchases 800 Shares of Humana Inc. (NYSE:HUM)

Mn Services Vermogensbeheer B.V. boosted its position in Humana Inc. (NYSE:HUM) by 1.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 48,012 shares of the insurance provider’s stock after acquiring an additional 800 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Humana were worth $12,181,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in HUM. AMF Tjanstepension AB boosted its stake in shares of Humana by 166.8% during the 3rd quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after purchasing an additional 25,041 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Humana by 12.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,090 shares of the insurance provider’s stock valued at $1,295,000 after purchasing an additional 461 shares in the last quarter. AustralianSuper Pty Ltd boosted its stake in shares of Humana by 35.2% during the 3rd quarter. AustralianSuper Pty Ltd now owns 2,495 shares of the insurance provider’s stock valued at $790,000 after purchasing an additional 650 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its stake in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Finally, CacheTech Inc. boosted its stake in shares of Humana by 5.7% during the 3rd quarter. CacheTech Inc. now owns 7,818 shares of the insurance provider’s stock valued at $2,476,000 after purchasing an additional 422 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Up 3.6 %

HUM opened at $270.91 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a 50 day moving average price of $271.11 and a 200-day moving average price of $287.34. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The stock has a market capitalization of $32.68 billion, a price-to-earnings ratio of 27.23, a PEG ratio of 2.05 and a beta of 0.56.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Equities research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.31%. Humana’s payout ratio is 35.58%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on HUM shares. Piper Sandler lifted their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. TD Cowen boosted their price objective on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Truist Financial boosted their price objective on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Nineteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and an average price target of $285.68.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.32% of the stock is owned by corporate insiders.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.